ANI Pharmaceuticals Inc (ANIP) 2025 Q4 法說會逐字稿

Good day everyone and welcome to today's ANI Pharmaceuticals Inc. fourth quarter and full year 2025 earnings results call. (Operator Instructions). It is now my pleasure to turn the conference over to Courtney Mogerley. Please go ahead.

Thank you, Erica. Welcome to ANI Pharmaceuticals fourth quarter and full year 2025 earnings results call. This is Courtney Mogerley, investor relations for A&I.

With me on today's call are Nikhil Lalwani, President and Chief Executive Officer, Stephen Carey, senior Vice President and Chief Financial Officer, and Chris Mutz, senior Vice President and head of ANI's rare disease business.

You can also access the webcast of this call through the investors section of the AI website at anipharmaceuticals.com. This call is accompanied by a slide deck that can be accessed by going to the events section of the investors page of our website. You can turn to our forward-looking statements on slide two.

Before we begin, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation, or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act.

These forward-looking statements are based on information available to ANI's pharmaceuticals management as of today, and involve risks and uncertainties, including those noted in our press release issued this morning and our filings with the FEC.

Going such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. ANI specifically disclaims any intent or obligation to update these forward-looking statements except as required by law.

During this call, we will also refer to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered as an alternative to financial measures required by GAAP. The non-GAAP financial measures referenced on this call are reconciled to the most directly comparable GAAP financial measures in a table available on the slide deck accompanying this call.

The archived web webcast will be available for 30 days on our website, ANI Pharmaceuticals.com. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on February 27, 2026.

Since then, ANI may have made announcements related to the topics discussed, so please reference the company's most recent press releases and SEC filings. And with that I'll turn the call over to Nikhil lalwani.

Thank you, Courtney. Good morning, everyone and thank you for joining us. 2025 was another year of outstanding execution and growth by the ANI team, highlighted by our remarkable results in the fourth quarter. At the core of everything we do is our purpose of serving patients, improving lives.

With our progress in the last year, we are well positioned to continue delivering on that purpose in 2026 and beyond. Starting with slide four, in 2025, the company delivered record revenue, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS driven by strong performance across our rare disease and genetics business units.

For the full year, we grew total company revenues by 44% year over year and adjusted non-GAAP EBITDA by 47% year over year. In addition, we delivered exceptional growth for our lead rare disease asset, corticotropin, with full year revenues up 76% year over year as we meaningfully expanded our reach in under penetrated specialty indications and served more patients.

With our strong R&D and operational capabilities, our generics business continued to outperform, growing 28% year over year in 2025. Turning to slide five, we believe the momentum we generated in 2025 positions us for continued growth in 2026. Our priorities for this year are threefold. First and foremost, AI's transformation into a leading rare disease company.

For our lead asset, Cortrophin gel, we plan to maximize its multi-year growth opportunity by addressing the significant unmet need across indications. We will continue to build on our momentum in the key under penetrated specialty indications in nephrology, neurology, rheumatology, ophthalmology, and pulmonology.

In addition, we're building and deploying a 90 person organization dedicated to acute gouty arthritis flares. For this expansion, we plan to capture sizable and unique additional opportunity in gout through expanding awareness and adoption of corticotropin for appropriate patients by newly identified physicians in podiatry and primary care.

For alluvium, we are focused on returning the product to growth by leveraging the commercial and patient access initiatives established in 2025. Importantly, we continue to believe in the long-term potential of ILUVIEN, as we believe the addressable patient populations across DME and NIU-PS are at least 10x the current number of patients treated with ILUVIEN today.

Our second priority is continued execution in our generics business by leveraging our superior R&D capabilities, operational execution, US-based manufacturing. And business development expertise as well as maintaining our current cadence of 10 to 15 launches annually.

We continue to make progress on this priority and anticipate another year of strong performance and cash generation from our genetics business that will enable us to further invest in our rare disease. Our third priority is executing a disciplined capital allocation strategy.

We are focused on driving organic growth by investing in our dedicated organization for Cortrophin in acute gouty arthritis flares and investing a high single-digit percentage of generics revenue into generics R&D. And to drive inorganic growth by exploring opportunities to expand the scope and scale of our rare disease.

Turning to slide six. We believe the three 2026 strategic priorities will drive long-term growth and value creation for the company. In 2026, we expect to deliver over $1 billion in revenue representing 23% growth over 2025 at the midpoint of our guidance range.

Rare disease is expected to account for approximately 60% of our total revenues in 2026, with Cortrophin gel growing 60% year over year. We also expect to expand the bottom line with adjusted EBITDA forecasted to grow 23% year over year at the midpoint of our guidance range. Later in the call, Steve will provide more detail on our 2026 guidance.

In summary, 2025 was a pivotal year for A&I as we delivered record performance and drove significant growth across the business lines. We are entering the year from a position of strength and are focused on executing on our three strategic priorities.

We anticipate that our virtuous cycle of growth in which our generics and brands businesses generate meaningful cash flows to support our rare disease business will drive our transformation into a leading rare disease company. And I'll turn the call to Chris to discuss our rare disease business in more detail, Chris.

Thank you, Nikhil, and good morning, everyone. Starting with slide seven, looking at 2025, I'm proud of our team as we closed out the year strong, delivering another excellent quarter marked by significant growth for Cortrophin gel as we expanded our reach in under penetrated specialty indications.

During the fourth quarter, the number of cases initiated and new patient starts reached another record high, and we saw broad growth across all of our targeted specialties, rheumatology, nephrology, neurology, pulmonology, and ophthalmology.

Prescribing for cortrophin gel and acute gouty arthritis flares remained a key growth driver this quarter. This indication is unique to Cortrophin gel among ACTH therapies and represented approximately 15% of total utilization. Notably, gouty arthritis has also been a strong catalyst for new prescriber additions, including many providers who were previously unfamiliar with ACTH.

We also continue to realize meaningful revenue synergies in ophthalmology. With fourth quarter Cortrophin gel volumes in ophthalmology over two times that of the same period a year ago, ophthalmology remains a fast-growing targeted specialty for Cortrophin gel, and we believe there is further upside as we expand awareness of Cortrophin gel for patients with severe allergic and inflammatory eye conditions.

Turning to slide eight. Looking at the market more broadly, the ACTH space has returned to growth following the launch of Cortrophin gel in 2022 and approached $1 billion in sales in 2025. We expect it to increase significantly in 2026 with Cortrophin gels growing by 55% to 65%.

Turning to slide nine, we continue to believe that the addressable patient populations across our key indications remain significantly under penetrated. For example, there are roughly $10 million patients in the US with gouty arthritis, about 36% receive treatment annually, and they have 1.5 to 2 flares on average per year. And about 8% of those patients with severe gouty arthritis, an injectable treatment for their flares.

This group of 285,000 patients represents our addressable patient population. Importantly, prescribers who were previously naive to ACTH represent approximately half of our total Cortrophin gel prescriber base, and this cohort continues to expand. We believe the most significant opportunity for growth is through overall expansion of the AC market by addressing unmet needs of appropriate patients.

To capture the multi-year growth potential of Cortrophin gel, we continue to focus on three key strategic priorities outlined on slide 10. We're investing in high ROI commercial initiatives. Building on the commercial expansion we executed in 2025. We are now taking the next step to capture the unique opportunity for cortrophin gel and acute gouty arthritis flares with our new 90-person dedicated organization.

There are several reasons why we are confident about the opportunity in acute gouty arthritis flares. As I highlighted earlier, there's a large addressable patient population of 285,000 patients. Second, Cortrophin gel is the only approved ACTH therapy for acute gouty arthritis flares.

And third, we have a proven track record in this indication. Prescribing for acute gouty arthritis flares represented approximately 15% of Cortrophin gel use in 2025. In addition, we ran successful pilots across 10 territories in primary care and podiatry. This gave us further confidence to expand our organization to capture the opportunity in acute gouty arthritis.

The hiring process is underway and we expect to deploy this team by mid-year. While we anticipate the expansion to the impact, impacting Croin gel volumes in the second half of 2026, we expect a greater impact in 2027 as the team reaches full productivity.

Additionally, we continue to focus on enhancing patient convenience. Our cortrophin gel prefilled syringe offering, which we launched in April of last year, simplifies administration and provides a more convenient option for patients. The launch of the prefilled syringe has been well received by both patients and prescribers and continues to support broader adoption and serve as an important growth driver for cortrophin gel.

Finally, we continue to invest in generating robust clinical evidence to support physician decision making and confidence in cortrophin gel. As part of this effort, we are advancing a 150-patient phase four study in acute gouty arthritis flares.

This trial, along with ongoing collection of pre-clinical and real-world data across core indications, is designed to reinforce Cortrophin gel's differentiated non-steroidal mechanism of action and provide insights that may support adoption and treatment guidelines.

We also continue to generate robust preclinical data for our key stakeholders on cortrophin gel's differentiated mechanism of action across multiple disease states. This remains a critical growth initiative as expanding the body of evidence supporting cortrophin gel's use across indications helps physicians make more informed treatment decisions.

On slide 11, turning to our retina franchise, we are continuing to advance several initiatives to support ILUVIEN sales. Our fully onboarded commercial team is focused on educating and engaging the retina community, and we are ramping up peer to peer educational programs and field activities with updated marketing materials to enhance physician understanding of ILUVIEN and its two indications.

In June of last year, we began promoting ILUVIEN under the combined label for chronic NIUPS and DME. Our sales teams have been educating customers nationwide while our market access team worked with pairs to establish coverage for the new chronic NIU-PS syndication. ALL seven Medicare administrative contractors, or MAC, have now updated their policies to cover alluvium for NIU-PS.

Among the TOP20 commercial payers, all those with ILUVIEN-specific policies have updated them to reflect both DME and NIU-PS indications. We also implemented initiatives to help physicians practices navigate ongoing Medicare market access challenges that have persisted.

As a reminder, patient support foundations such as Good Days had limited funding in 2025, affecting their ability to assist Medicare patients with copay support across retina products. Our team has gained traction with leading retina practices, helping them explore pathways to secure ILUVIEN for eligible patients under the Medicare Part D benefit using a specialty pharmacy, the same approach used for cortrophin gel access.

In addition, we continue to share results from our new day study of alluvium in patients with DME which were presented at prominent medical meetings, including most recently at the Flow Retina International Congress in December and the Hawaiian Eye and Retina Conference in January. With that, I'll turn the call over to Steve for the financial update, Steve.

Thanks, Chris, and good morning to everyone on the call. I'll review our fourth quarter and full year 2025 results and 2026 guidance in more detail. In 2025, we delivered on our financial commitments, generating robust top and bottom-line growth and significant cash flows.

Starting on slide 12, ANI recorded revenues of $247.1 million in the fourth quarter, up 30% over the prior year period. For the full year 2025, ANI generated record revenues of $883.4 million, up 44% versus 2024.

Cortrophin gel in the fourth quarter were a record $111.4 million, up 88% from the prior year, period. In 2025, Cortrophin gel delivered $347.8 million of net revenue, up 76% year over year, driven by strong adoption across neurology, nephrology, rheumatology, pulmonology and ophthalmology.

Alluvia net revenues were $19.8 million in the fourth quarter and$74.9 million for the full year 2025. Revenues for generics in the fourth quarter were $100.8 million. An increase of 28% over the prior year. The outperformance for the quarter was driven by continued strength in the partner generic launch that occurred in the third quarter of 2025.

Full year revenues in 2025 for generics were $384.1 million, an increase of 28% over the prior year, reflecting our strong R&D capabilities, execution, and steady cadence of new product launches. Now moving down the P&L on slide 13. As a reminder, when I speak to our operating expenses, I will be referring to our non-GAAP expenses, which are detailed in table three in our press release.

Generally, our non-GAAP operating expenses exclude depreciation and amortization, stock-based compensation, and certain costs related to litigation and M&A activity. Please refer to table for a full reconciliation to our GAAP expenditures.

Non-GAAP costs of sales increased 43% to $99.8 million in the fourth quarter of 2025 compared to the prior year period, primarily due to net growth in sales volumes and significant growth of royalty bearing products.

Non-GAAP gross margin in the fourth quarter was 59.6%, a decrease of approximately 400 basis points from the prior year period. Principally due to product mix, including significant growth of royalty bearing products, including Cortrophin and a partner generic product that was launched in the third quarter, as well as lower brand revenues.

For the full year of 2025, non-GAAP costs of sales increased 44% to $339.5 million compared to the year before, and non-GAAP gross margin was 61.6%, down approximately 10 basis points from the prior year. Non-GAAP research and development expenses were $11.7 million in the fourth quarter, a decrease of 27% from the prior year, period, driven by timing of rare disease and generic programs.

For the full year of 2025, non-GAAP research and development expenses increased 18% to $49.5 million compared to the year before due to higher investment to support future growth of our rare disease and generics businesses.

Non-GAAP selling, general and administrative expenses increased 28% to $70.2 million in the fourth quarter, driven by spend for our new larger ophthalmology sales team promoting Cortrophin gel and ILUVIEN and continued investment in rare disease sales and marketing activities. Including the expansion of the rare disease team in the first quarter of 2025.

For the full year of 2025, non-GAAP selling general and administrative expenses increased 46% to $264.6 million. Adjusted non-GAAP diluted earnings per share was $2.33 for the fourth quarter compared to $1.63 per share in the prior year period. For the full year of 2025, non-GAAP diluted earnings per share was $7.89 compared to $5.20 the year before.

Adjusted non-GAAP EBITDA for the fourth quarter was $65.4 million, up 31% compared to the prior year period. And was $229.8 million for the full year, up 47% compared to the prior year. We ended the fourth quarter with $285.6 million in unrestricted cash, up $140.7 million as compared to the $144.9 million as of December 31, of the prior year.

Cash flow from operations was $30.4 million in the fourth quarter of this year and $185.2 million on a five full year basis. As of December 31, 2025, we had $629.1 million in principal value of outstanding debt, inclusive of our senior convertible notes and term loan. At the end of the fourth quarter, our gross leverage was 2.7 times and our net leverage was 1.5 times our full year adjusted non-GAAP EBITDA of $229.8 million.

This morning, we are pleased to reaffirm our 2026 financial guidance, which reflects significant top and bottom-line growth. Our guidance outlined on slide 14 is as follows 2026 net revenue of $1.055 billion to $1.115 billion, representing year over year growth of approximately 19% to 26%.

Cortrophin gel net revenue of $540 million to $575 million, representing year over year growth of 55% to 65%, driven by continued volume gains. Consistent with par years and typical industry dynamics, we expect first quarter Cortrophin gel revenues to be down sequentially from the fourth quarter and to represent approximately 13% to 14% of total 2026 revenues, slightly lower than in 2025,

when the first quarter accounted for approximately 15% of full year revenues. This effect is driven by two factors. First, we are experiencing typical seasonality related to the impact of insurance re verifications, which appear to be taking slightly longer as compared to the prior year.

Due to increase Cortrophin patient volume in the physician's offices and in some parts of the country, due to weather related physician office closures that temporarily delayed the re verification process.

While these factors impacted January, we have since seen a 25% jump in volumes dispensed, and acceleration in new patients starts in February, and are confident that the momentum will persist in March as physician offices complete work through the re verifications backlog.

Second, our full year Cortrophin guidance is inclusive of initial script volume expected to result from our 90-person organizational expansion to support our gouty arthritis flares indication. Revenues associated with this expansion will first occur in the third quarter and are expected to build momentum throughout the fourth quarter.

As we look farther out into the year, we remain confident in our full year guidance and the significant multi-year growth opportunity for Cortrophin gel. We expect very significant sequential growth in the second quarter as typical first quarter dynamics subside.

We then expect further sequential gains in the third and fourth quarters driven by continued performance of our portfolio, pulmonology and ophthalmology teams, in addition to the full deployment by the end of the second quarter of our new 90-person organization focused on acute gouty arthritis flares.

We expect ILUVIEN net revenue of $78 million to $83 million, representing year over year growth of approximately 4% to 11%. We expect adjusted non-Gap EBITDA of $275 million to $290 million, representing year over year growth of approximately 20% to 26%.

And from a quarterly cadence perspective, we expect adjusted non-Gab EBITDA to be down sequentially in the first quarter and modestly down as compared to the first quarter of the prior year driven by quarterly revenue dynamics.

We then expect sequential growth in the remaining quarters of the year, with the fourth quarter representing the highest quarter by a significant amount driven by incremental contribution from our gout focused team expansion. We expect adjusted non-GAAP earnings per share between $8.83 and $9.34 representing year over year growth of approximately 12% to 18%.

We expect adjusted gross margin to be 59.3% to 60.3% in 2026, which is down from 2025, driven by significantly higher forecast sales of royalty bearing products, the non-recurrence of revenues from our first half, 2025, 180-day exclusive launch of Cortrophin, and the expectation of lower brand sales.

We currently anticipate a full year US GAAP effective tax rate of approximately 26% to 28%. And consistent with prior quarters, we will tax effect our non-GAAP adjustments for computation of adjusted non-GAAP diluted earnings per share, utilizing our estimated statutory rate of 26%.

We anticipate between $21.5 million and $21.8 million shares outstanding for the purpose of calculating full year non-GAAP diluted EPS. And finally, please note that we will continue to exclude from our adjusted non-GAAP diluted EPS calculation the diluted shares included in GAAP diluted EPS which are expected to be offset in full by the cap call transaction. With that, I'll turn the call back to Nikhil.

Thank you, Stephen. Turning to slide 15, in closing, we delivered a remarkable 2025 characterized by significant growth across Cortrophin gel and outperformance in our genetics business. We've entered 2026 in a position of strength and remained focused on achieving our strategic priorities, including accelerating our transformation into rare disease.

Continuing to execute in generics and deploying capital in a disciplined manner. Overall, we expect to deliver over $1 billion in revenue in 2026, with rare disease representing approximately 60% of total revenues. With that, operator, please open the line for questions.

(Operator Instructions)

Glen Santangelo, Barclays

Yeah, thanks for taking my question. Good morning, everyone. Hey, Nikhil, obviously Korroin continues to surprise on the upside, and you sort of make the case that you believe there's a multi-year opportunity here as you expand into these under penetrated indications and, you're obviously investing in the salesforce to TRY to take advantage of that without giving us guidance beyond 2026.

I don't. If there's any high-level commentary you can sort of give us to help us think about how meaningful this multi-year opportunity could be, and I, I'm guessing, you're starting to think about a peak sales number, maybe it's a little bit premature, but how do you think about that?

And then, my follow-up for Steven's going to be, the royalty steps up this year, can you help us think about how that royalty is going to step up so we can sort of better model gross margins going forward? Thank you.

Yes, good morning and thank you for your question, Gwen. Look, I think, we believe in the significant multi-year growth opportunity for Cortrophin, and I think the key really is slide nine in our deck from this morning where we highlight, the addressable patient populations across indications, and these are significantly under penetrated, not just by us but across the ACTH category.

So we believe that there is a much larger number of patients that are yet to, that are appropriate for ACTH therapy that are yet to benefit from this therapy.

So, we see, a significant multi-year growth runway for the for the for the category and also for Cortrophin and we're investing, to build momentum in 26' and beyond, right? So IROI commercial initiatives like the. 90% organizational expansion for gout, but we did an expansion last year. We're enhancing convenience, we launched a prefilled syringe last year.

We're continuing to evaluate opportunities to further enhance patient convenience and importantly, we're generating both scientific and clinical evidence. We'd a phase four clinical trial. We're advancing a phase four clinical trial for Cortrophin and gout, as well as a robust pipeline of investigator-initiated trials across disease straits, so.

We believe in the strong multi-year growth opportunity and in our investing to ensure that we can. Capture that opportunity and we again, we believe in the opportunity for the category as a whole to keep growing for several years.

And then your second question on the on the Merck royalty. In 2025, annual revenues of Cortrophin gel reached a level by which we surpassed the highest royalty tier for incremental net sales. The way in 2025 itself we were in the highest royalty tier for the royalty, and then we currently anticipate the blended royalty rate to be in the high 20s in 2026. Thank you, Glen.

Okay, yeah, thanks for the comments.

David M. Selim, Piper Sadler

Thanks. So I had two on Cortrophin. So one. I'm trying to get a better sense of how you're thinking about operating leverage going forward. So you're adding the 90 reps, you're calling on primary care, you're calling on podiatrists. I'm just wondering how promotion intensive you perceive the gout indication to be and what that means for potentially further expansion.

So just help us understand that and how you're thinking about operating leverage. That's number one. And then number two is you're thinking about. Indications like sarcoidosis and ophthalmic indications.

Can you talk about the number of vials used or duration of treatment and those kind of indications versus gout, and what I'm trying to get at is the quote unquote value of a given patient across the different opportunities within the Cortrophin franchise. So if you could help us provide color there, that would also be helpful Thank you.

Great. Good morning and thank you for your question, Dave. So, The first question on operating leverage. Look, we're instilled in high growth mode, and we continue to balance growth and profitability as we drive that growth, right? So when you look at 2025, our guidance implies, even the growth of 20% to 26%.

And the EBITDA margin as a percentage of growth, as a percentage has stayed the same in our 2026 versus 2025 despite a year of very significant investment in this 90% organization for growth and then also related op ed, so the total.

Implied OpEx increase at the midpoint of our guidance is about $50 million, majority of which is for the gout expansion, and despite that, we're keeping the EBITDA margin percentage the same in 26' versus 25'.

We Strongly believe that, as we have seen even with the expansion last year of the of the sales force that you will see partial impact from the organization expansion for gout in 2026 and we'll see full impact in 2027, right? So the full year impact and the, because it takes the sales force, we'll have them in place by midyear.

They'll have impact in Q3 and Q4 and then you'll see full impact in 2027 obviously driving operating leverage. So that's the question on operating leverage and look. I think the key is in terms of further expansions, the key is the addressable patient population, right?

As we currently have a combined team that details into nephrology, neurology, and rheumatology. We expand that's called our portfolio team. We expanded that team in 2025, right? We still have a much larger addressable patient population that we can address not just in these three therapeutic areas but across areas, so.

With an ability to reach physicians and reach patients, there will be a benefit from further expansions, obviously, but that's down the field as we capture this multiple, multi-year growth opportunity. The key in terms of the current year investment.

We're seeing impact in this year retaining the margin percentage and then going forward in 2027 we'll see, a much bigger impact with the same with the same level of SG&A as this year. Your second question was on the duration of treatment across indications. The duration of treatment does indeed vary. Sarcoidosis has a much longer, in use and more vials per patient.

Whereas acute gouty arthritis flares as a lower number of vials per patient. That is appropriate at the time of the exacerbation or flare. So, you know there is a variance across the nations that that we serve with gel. Thank you, David.

Vimal Daniel, Guggenheim securities

Great, thanks for taking my question. So maybe one more on Korro and I could start building on the earlier question. So this additional 90-person organization you're saying is dedicated to the gouty, opportunity in targeting mainly primary care and podiatry.

I'm just trying to get a sense of Again, sort of the leverage or the opportunity for them to do other things beyond just gouty arthritis, can, will they be going to any other specialties, or are there other indications they'll be focusing on, or is it strictly just for gouty arthritis, just trying to get something into the ability to leverage that additional investment,

and then second, question is more for Steve on the business development side. And I've talked about investing in kind of expanding the outer disease, opportunities here. I'm just trying to get a sense of given where your leverage is now,

so, what you're willing to do in terms of leverage versus, using equity or kind of as you think about the size of potential deals, what you're thinking about in terms of options for financing those sorts of opportunities Thanks.

Good morning and thank you. So on the 90-person organization. That's for gout, and as a clarification, not all 90 are in sales, so majority of that 90-person group is sales expansion, but there are obviously patient support operations and marketing and other support areas too. But yes, that Organization and the sales organization and the rest of the organization can be leveraged.

Both for Other indications that they treat, so primary care and podiatry do treat other indications that krofen is indicated for. Our focus is primarily on gout, but there are other indications potentially that they can treat, which are, of course, are for the appropriate patients.

So it can be leveraged for that. But in addition, that sales force can also be leveraged by adding another product in the basket just like we did for ophthalmology. So that option is available. Obviously the opportunity in acute gouty arthritis flares is very significant. We've identified 7,000 ACPs that treat the most severe acute gouty arthritis flares patients, and that is our, that is the primary focus of this expansion.

And that is what we will be focused on as we put this team in place by midyear and look, we've made, very good progress on the recruitment. We have our sales leadership and the area business directors in place and we're now moving to recruitment of the sales team members, and we will launch by midyear so.

On the and are reasons to believe. Are number one, the large under penetrated market opportunity and Cortrophin is the only approved ACTH product with this indication. Second is we have a successful track record in gout, plus of our volumes in 2025 coming from gout in rheumatology and nephrology.

And number three are successful pilot programs across 10 territories in primary care and podiatry offices which we ran in 2025, right, but see the most severe acute gouty arthritis flares patients.

And so we saw success with those pilot programs and that gave us the confidence to deploy this larger sales force and the and the larger organization in an in an indication where we have the indication and is and we are the only ACTH product available right? So with the field force deploying the mid wear we expect to see.

In in Q3 and Q4 like we saw like we saw in 2025 when we did the expansion for our portfolio sales force and then we'll see the full realization in 2027, right as we're expanding our field force we're also investing in clinical evidence generation through a phase four trial to expand usage over time.

So that's on the gout expansion and then your second question on the merc royalty, right, look, I think. We've, in, we're always evaluating potential opportunities. But we do not comment on active or non-active business development initiatives, especially with our partners, and thank you for your question, Dennis Thank you.

Ekaterina Knyazkova, J P Margon

Thank you so much. Just one for me. So just on Cortrophin gel, have you seen any recent changes on the patient access frond? Just are you seeing any payers or plans giving more trouble or coverage, or reimbursement, or are you seeing kind of trends that are similar, as you were seeing last year? Thank you.

Good morning and thank you for your question, Katrina. Look, we TRY to find a balance between sharing information that is, helpful to investors and that is competitively sensitive. Having said that, at an overall level, we have not seen material changes from a, from an access perspective.

Again, we're targeting, or we're reaching, trying to reach, the appropriate patients as a, late line therapy for, with Cortrophin gel. Thank you for your question, Katrina.

Thomas Smith, Leerink Partners.

Hey guys, good morning. Thanks for taking the questions two on Cortrophin if I could. You mentioned that about 15% of utilization came from acute gouty arthritis in 25'. Could you just give us a sense of, what your expectations are for where that number goes in 26' and 27', given the salesforce expansion efforts?

And then, could you give a little bit more color on the core trope and pilot programs executed in primary care and podiatry? Any details? I guess on specific feedback from those prescribers versus your other specialty types and any specific learnings you're implementing to help better target those offices. Thanks so much.

Yeah, good morning and welcome to your first ANI conference call. Tom, great to have you. So, the first question is on, our current business in about 15% of our volume comes from gout as we deploy this, targeted sales force and broader organization, we do expected to increase, significantly.

We're not putting a number to it at this time, but we'll keep you updated obviously on our progress. I think the important thing to highlight here is that, if you look at the ANI Cortrophin story a big part of that success has been being able to reach new physicians. Almost half of our physicians that have prescribed krofen were naive to the category.

ACTH prior to the entry of gel. And if you think about and this dovetails into your second question around the pilot programs. If you think about the ACPs that were reaching through this expansion.

You know we're targeting, we're trying to reach about 7,000 ACPs that we've identified across territories, right? Majority of these, right? Obviously some were part of the pilot programs that we had across 10 territories, but most of these have not been, and so that will further expand, right? And the success we've had in being able to reach new physicians, right?

Will continue that has given us confidence and will continue as we reach the new primary care and podiatry care physicians, right? So what we'll also expand is not just the gout volumes as a percentage of, Cortrophin volumes, but also the number of physicians and number of new physicians that were naive to ACTH.

And then going back to your second question regarding, or I guess the second part of your second question on The pilot programs, I think that we've had, a lot of learnings in terms of the discussion to be had with the primary care and podiatry physicians in terms of identifying the appropriate patients.

You know how to work with their offices to work through the enrollment to fulfillment process and then also learnings on, primary care and podiatrists are very large sort of number of numbers of. ACPs that are there in the country, but really figuring out the 7,000 that treat the most severe acute gouty arthritis flares, how do you identify them with the claims and other data that is available?

So that you're reaching the appropriate patients. That's been part of our learning through the pilot programs through 2025. And thank you for your question, Tom.

Les Slowsky, True Securities

Good morning. Thank you for taking my questions. Congrats on the progress three for me Cortrophin. First, you noted that 15% of utilization is coming from gout.

How would you expect that trend to uptake once the new team is in place? And is this a good representation of the percentage of the total consultant revenues? And then will you have some of the results in phase four trial in time for the Salesforce expansion?

And the second, on ILUVIEN, can you provide an update on the specialty pharmacy progress and perhaps just kind of your thoughts on the patient access, and then lastly on generics, how are you thinking about product cadence and erosion as we move through the year? Thank you.

Yeah, good morning and thank you for your questions, Les. I'll take them one by one. So, the first question on the gout, we do believe that the 15% of volume of current volumes will expand, right, as a percentage of total volumes, with this investment, so we will see a significant update. We will, update you as we move along.

On the trial, we are, the trial, the phase four trial is progressing, and we will provide meaningful updates as the trial progresses if the. The organization expansion, right, we've already hired, as I said, the sales leadership and the ABDs, the business directors. The organization will launch in full by midyear.

The results of the trial will not be in place by then, so that's, on the come later on, and we'll obviously, provide updates, on the trial the second question was on ILUVIEN.

So, on ILUVIEN, we continue to make progress in the growing use of the alternative access channels to navigate the market access challenges for, Medicare patients. We are seeing prominent practices adopting this alternate, workflow and use of alternate channels, and, it's basically patients that have access to the drug benefit and,

that's the same procedure that or process that we use and workflow that we use for Cortrophin and so we've seen prominent retina practices use it now what we, what has happened with the foundation funding is we have seen some early contributions to the funding earlier this year and though.

This hasn't had a meaningful impact on patient access to ILUVIEN, it was open for a few days and then it was, closed back.

So, our guidance for 2026 does not assume that the funding will return in any meaningful way, and we will continue to closely monitor the situation and of course stay focused on, growing the use of the alternative access channels to navigate the market access challenges in addition to the strategic investments in marketing

and medical affairs to support the increased awareness of the new day clinical data for DME establishing the coverage for both DME and NIUPS and then obviously the strengthened commercial team and further enhanced promotional efforts.

So that's on ILUVIEN and then finally your question on the genetic cadence, we are continuing to have a strong cadence from our driven by our R&D capabilities of 10 to 15 launches that'll help support growth of the genetics business and. Cash flow generation that we are reinvesting into rare disease to accelerate the transformation of ANI into a leading rare disease company. And thank you for your questions, Les.

Brandon Folks, HC Wainwright

Hi, thanks for taking my question and congrats on the progress. Maybe just sort of following on from the line of questioning on Cortrophin. Outside of gout, is there any way you can just give us some color in terms of how you're seeing the ACT market shape up?

Are prescribers choosing one product over the other or are prescribers using both where they can? You talked about adding new prescribers. Can you just help us think through when you convert these new prescribers, are you generally converting them to sort of be Cortrophin prescriber or an ACTH?

Believer and prescriber, and what I'm trying to get to is how competitive is the next script, for a potential ACTH patient right now versus a continued market expansion? How long do you see sort of the Market expansion playing out versus market expansion as well as share capture between the two and the category driving growth. Thank you.

Yeah, good morning and thank you for your question, Brandon so, I think your first question was on the ACTH market beyond gout and I think that, we'll just point to a couple of couple of points. Number one is that we see growth across indications across the core indications that we launched with, which is, in in rheumatology, nephrology, and neurology.

In addition to pulmonology and ophthalmology. If you think about the ANI's growth in Cortrophin in 2025, the 75% to 76% growth in rofen. A significant portion of that came from just growth across all these specialties outside of gout. Now gout also was a driver, but there was significant growth across these other specialties too, and it really the thing that's underpinning, and that really goes to your second question around.

The competitive situation, I mean this is to us not about. About share capture at all. This is about market expansion, reaching the appropriate patients, and the addressable patient population is very significant. And highly under penetrated, right, so it's significantly under penetrated across indications and so. The fact that two players are out there.

Trying to address the appropriate patient ultimately supports the overall market growth and, ensures that the appropriate patients get the benefit of ACTH treatment for their indications, and then, maybe to the last part of your question which was, We are, our team is out there trying to convince.

And this is a little bit on a lighter note, but our team is out there trying to convince patients, I'm sorry, trying to con physicians of the appropriate patients, for Cortrophin, right? And not the broader ACTH category. So, thank you for your questions, Brandon.

And I would like to now turn the call back over to Nikhil lalwani for closing remarks.

Thank you everybody for taking time to join the AI. Discussion we look forward to updating you on our progress and are looking forward to a strong 2026 thank you so much and we will remain focused on our purpose of serving patients, improving lives.

Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.